Application of euphorbia jolkini lactone B derivative in drug for treating chronic obstructive pulmonary disease

A petroseolactone and chronic obstructive technology, which is applied in the field of medicine and can solve the problems that the therapeutic effect of chronic obstructive pulmonary disease has not been reported.

Inactive Publication Date: 2018-05-08
JILIN UNIV
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Previous studies by the inventors have shown that petroglide B and its derivative HJB-1 inhibit LPS-induced macrophage activation and acute lung injury (Xu X, Molecules. 2016 J

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of euphorbia jolkini lactone B derivative in drug for treating chronic obstructive pulmonary disease
  • Application of euphorbia jolkini lactone B derivative in drug for treating chronic obstructive pulmonary disease
  • Application of euphorbia jolkini lactone B derivative in drug for treating chronic obstructive pulmonary disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] The application of a petroglide B derivative in the medicine for treating chronic obstructive pulmonary disease, the structure of the eupholactone B derivative HJB-1 is as follows:

[0020]

[0021] A pharmaceutical composition, containing an effective dose of euphoride B derivative HJB-1 and a pharmaceutically acceptable carrier.

[0022] The pharmaceutical composition can be tablet, capsule, pill, injection, sustained-release preparation, controlled-release preparation or microparticle drug delivery system.

[0023] The compounds of the present invention may exist in the form of isomers.

[0024] The effects of the present invention will be further illustrated below through activity experiments.

[0025] (1) Establishment of COPD model of mouse chronic obstructive pulmonary disease

[0026] The mouse COPD model was established by fumigation, and the mice were placed in the poisoning box of the PAB-S200 passive smoking animal poisoning system. There were two small...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of a euphorbia jolkini lactone B derivative in a drug for treating a chronic obstructive pulmonary disease, and belongs to the field of medicines. In the application, a pharmacodynamic experiment is performed on a mouse model with the chronic obstructive pulmonary disease by adopting a compound; a result shows that HJB-1 has an obvious effect of improving lungtissue lesions of the mouse with the chronic obstructive pulmonary disease and a function of decreasing the number of inflammatory cells in bronchoalveolar lavage fluid of the mouse with the chronic obstructive pulmonary disease; the euphorbia jolkini lactone B derivative is used for developing the drug for treating the chronic obstructive pulmonary disease.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the medical use of a diterpene compound extracted and separated from chamaejasma chamaejasme, in particular, the application of the compound in the preparation of medicines for treating chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by persistent obstruction of airflow from the lungs. The disease presents with a slowly progressive natural history and is an irreversible and life-threatening chronic lung disease that obstructs normal breathing. Worldwide, more than 200 million people suffer from chronic obstructive pulmonary disease, which is listed as the fourth leading cause of death in the world. The primary cause of COPD is inhalation of cigarette smoke (including passive exposure), and increasing air pollution in developing countries has also increased the incidence of COPD. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/365A61P11/00
Inventor 孙万春刘宁
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap